<i>TERT</i> Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

<i>TERT</i> Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

Although the development of mitogen-activated protein kinase (MAPK) inhibitors has greatly improved the prognosis of <i>BRAF</i><sup>V600</sup> cutaneous melanomas, the identification of molecular indicators for mutated patients at risk of early progression remains a major is...

Full description

Bibliographic Details
Main Authors: Pauline Blateau, Etienne Coyaud, Estelle Laurent, Benoit Béganton, Vincent Ducros, Géraldine Chauchard, Julie A. Vendrell, Jérôme Solassol
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
<i>BRAF</i><sup>V600</sup>
melanoma
co-occurring mutation
<i>TERT</i> promoter
prognosis factor
targeted therapies
Online Access:https://www.mdpi.com/2072-6694/12/8/2224

Internet

https://www.mdpi.com/2072-6694/12/8/2224

Similar Items